使用生物作为参考药物的合成多 - - 欧洲监管批准的景观
Kevin Klein1, Jens Heisterberg2, Pieter Stolk1
1Exon Consultancy, Amsterdam, Netherlands.
Frontiers in medicine
|April 29, 2024
概括
化学合成的聚类药物参考生物原始体面临着独特的欧盟监管挑战. 本次审查强调需要更清晰的途径,以确保安全,高质量的后续产品.
科学领域:
- 制药科学 制药科学
- 监管事务 监管事务
- 生物技术是生物技术.
背景情况:
- 最近在合成药物制造方面的进步导致了化学合成的聚类产品,这些产品引用了生物原始物.
- 欧盟 (EU) 监管体系目前缺乏针对这些合成后续产品的专用途径,与生物类似药不同.
研究的目的:
- 审查最近在欧盟内参考生物原始物的合成的发展.
- 分析不同监管途径对评估,临床实践和药物监管的影响.
- 倡导提高监管这些产品的透明度和全球调整.
主要方法:
- 对欧盟合成调节的最新发展的文献综述.
- 对合成后续产品的现行监管框架 (第10条第1款和第10条第3款) 的分析.
- 讨论对监管评估,临床实践和药物监督的潜在影响.
主要成果:
- 化学合成的聚类产品引用生物原始物必须在欧盟通过传统的仿制或混合监管途径.
- 对生物类似药和合成后续产品的不同的监管方法会造成潜在的不一致性.
- 合成产品日益复杂,需要对当前的监管策略进行重新评估.
结论:
- 欧盟当前的监管格局对引用生物原始物的合成聚类产品提出了挑战.
- 不同的监管程序可能会影响这些重要的治疗剂的批准,临床使用和安全监测.
- 更大的透明度和国际协调对于确保安全,有效和高质量的合成仿制药的批准至关重要.
关键词:
生物类似药的生物类似药.复杂的通用药物复杂的通用药物混合应用程序 混合应用程序利拉格卢提德 (liraglutide) 是一种葡萄糖类药物.非生物复杂药物非生物复杂药物合成的多化物.皮制剂是一种皮制剂.治疗等价性的治疗.更多相关视频
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
581
06:26Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
986
相关概念视频
Bioequivalence: Overview
1.0K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.0K
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Preclinical Development: Overview
4.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Drug Nomenclature
1.7K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.7K
Drug Control Governance: Regulatory Bodies and Their Impact
157
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
157
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
